Program and book of abstracts 1st conference

1 st Conference of European Academy for Molecular Hydrogen Research in Biomedicine “Hydrogen for Biomedicine“

Qin Shucun

Dr. Shucun Qin received his BS fromHebei Medical University and PhD of Medical Science from PLA General Hospital, China. He completed post-doc training in Dr. Alan Tall laboratory at Columbia University, New York, NY and worked as a senior scientist at University of California at Irvine, VA Hospital Medical Research Institute, Long Beach, CA, U.S.A. Currently, he is a Professor and Director of the Institute of Hydrogen Biomedicine and Center for Biological Sciences Reasearch Shandong First Medical University at Jinan, China. Dr. Qin’s research interests include molecular and cellular mechanisms of aging, stress, and age-/stress-associated degenerative diseases with a focus on lipid and lipoprotein regulation of in vivo metabolism. He has published more 240 papers with more than 1,100 times citations (H-index 32) and has been elected as vice president of China Society of Atherosclerosis in 2010, president of the International Society of HydrogenMedicine and Biology in 2017, and president of China Society of Hydrogen Biological and Medical Research in 2020. ROLE OF HYDROGEN IN ATHEROSCLEROTIC DISEASE: FROM BENCH TO BEDSIDE Shucun Qin, M.D. & Ph.D. Shandong First Medical University, Jinan, China E-mail: scqin@sdfmu.edu.cn Atherosclerotic cardiovascular and cerebrovascular diseases are among the leading causes of morbidity and mortality worldwide. Given our recent understanding of its role as a small molecule antioxidant and anti-inflammatory agent, hydrogen may play an important role in preventing and treating atherosclerotic cardiovascular and cerebrovascular disease. In the past decade, more than 50 publications in the English language literature consider the role of hydrogen as an anti-atherosclerotic agent. we have focused on the pathophysiological characteristics and risk factors associated with atherosclerosis (AS) and the laboratory research data that studies on hydrogen to prevent and treat this condition, including the responses observed in both animal models and human studies. We have discussed the molecular mechanisms underlying the efficacy of hydrogen molecules with respect to atherosclerotic disease.

62